Research Roundup

Posted on Tuesday, November 1, 2011 - 10:00, By: ALSN Staff
C9ORF72 mutation is most common cause of familial ALS, FTD Two independent research teams have identified a mutation in the gene for chromosome 9 open reading frame 72 (C9ORF72) as the most common cause found to date of familial (inherited) ALS, frontotemporal dementia (FTD) and ALS with FTD (ALS-...

The registry, called fALS Connect, is for people with familial ALS and has the goal of hastening research progress in this disease

Posted on Friday, October 7, 2011 - 06:00, By: Amy Madsen
A new registry has been launched for people with the familial (inherited) form of amyotrophic lateral sclerosis (ALS). The Web-based fALS Connect registry was developed by a research team from the University of Miami Miller School of Medicine in Florida. The team aims to connect families affected...
Posted on Thursday, September 1, 2011 - 10:35, By: ALSN Staff
Disease 'in a dish' is a new tool for studying ALS An MDA-supported research team has created a human cellular model of ALS using cells taken from people with the ALS8 subtype of the disease, a familial (inherited) form of ALS (amyotrophic lateral sclerosis) caused by mutations in the VAPB gene.
Posted on Friday, July 1, 2011 - 13:37, By: ALSN Staff
Eating and breathing: A possible 'synergistic' effect in ALS Initial results of a multicenter pilot study to evaluate nutritional requirements and early intervention for breathing problems in ALS are helping scientists determine how physical factors such as body mass, diet and activity affect the...
Posted on Sunday, May 1, 2011 - 11:07, By: ALSN Staff
Reactivated virus may contribute to ALS Autopsy samples have shown a viral protein called HERV-K reverse transcriptase is much more prevalent in ALS brain samples than in brain samples obtained from people who died of other causes.
Posted on Tuesday, March 1, 2011 - 10:47, By: ALSN Staff
ALS TDI expansion among 2011 goals Building on progress made in 2010, the MDA-supported ALS Therapy Development Institute (ALS TDI) has outlined a number of milestones it plans to meet in 2011.   Steve Perrin, ALS TDI chief scientific officer and CEO at the nonprofit biotech in Cambridge, Mass...
Posted on Saturday, January 1, 2011 - 01:01, By: ALSN Staff
FDA approves emotional-expression medication